A New Milestone in the Development of Ocular Insulin Delivery

On 12 December 2025, the Intellectual Patent Office of the Philippines (IPOPHIL) issued a positive International Preliminary Examination Report (IPER) to Dr. David Gosiengfiao for his novel method of delivering insulin to the body via eye drops.

This recognition places the Philippines at the forefront of a new frontier in ophthalmic drug delivery, with applications in glaucoma, macular degeneration, diabetes, PCOS, Alzheimer's disease, Parkinson's disease, and other states of impaired cognition like brain fog, as well as migraine.

The Importance of This Advancement in Ophthalmic Drug Delivery

Delivering drugs through the eye offers several advantages:

• Non-invasive administration reduces discomfort and risk of infection.

• Rapid absorption through the ocular surface allows for quicker therapeutic effects.

• Targeted delivery minimizes systemic side effects.

• Improved patient adherence due to ease of use.

  
  

This technology could transform how medications are administered for neurologic and systemic diseases, making treatments more accessible and less burdensome.

Gratitude for Legal and Advisory Support

Navigating the legal and intellectual property landscape is crucial for bringing innovations to market. We sincerely thank the following for their invaluable support:

• Josel Bonifacio and Accolade IP for their expert guidance on intellectual property matters.

• Atty. "Dean Bong" JP Villasor, Atty. Neil Yanson, Atty. Liezl Cua-Andaya, Atty. Lorebette Grandea, and Atty. Marnie Tonson for their dedicated legal advice and assistance.

  
  

Their efforts ensured that the project secured the necessary protections for this groundbreaking technology.

Looking Ahead with Optimism

This positive IPER from IPOPHIL is a testament to what can be achieved through collaboration, innovation, and perseverance. The journey of developing insulin eye drops is just beginning, and the future holds exciting possibilities for expanding this technology to benefit many patients worldwide.

We remain committed to advancing this research and exploring new applications that can improve health outcomes. With continued support and dedication, we look forward to seeing this innovation make a real difference in people’s lives.